- Home
- SCWO vs TCRX Comparison
SCWO vs TCRX Comparison
Compare SCWO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | TCRX |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 64.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCWO | TCRX |
|---|---|---|
| Price | $2.60 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 244.6K | ★ 598.3K |
| Earning Date | 11-12-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,910,340.00 | ★ $8,423,000.00 |
| Revenue This Year | $5,945.19 | $286.83 |
| Revenue Next Year | $106.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 508.52 | N/A |
| 52 Week Low | $1.63 | $0.88 |
| 52 Week High | $10.90 | $2.85 |
Technical Indicators
Market Signals| Indicator | SCWO | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 56.58 |
| Support Level | $2.47 | $1.13 |
| Resistance Level | $2.65 | $1.27 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 82.63 | 71.50 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.